Navigation Links
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
Date:8/20/2008

bout PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology, which has been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, Celgene, CV Therapeutics and Schering-Plough. For more information, visit the company's website http://www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PTC124 Featured at Third Annual Congress of Myology
2. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
3. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
4. Atrium shows a strong financial performance for its first quarter
5. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
6. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
7. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
8. UW paper in Science shows how some solids mimic liquids on nanoscale
9. New research shows that iPods do not interfere with cardiac pacemakers
10. New kind of transistor radios shows capability of nanotube technology
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...EIJING,Nov.25/PRNewswire-Asia/--SinovacBiotechLtd....uncedtodaythatitexecuted,ajointventure(JV)agreemen...td.(SinovacDalian).TheJVwillresearch,develop,produ...ntributeitsexpertise,andexperienceindevelopingandc...llbringitslanduserights,manufacturingfacilitiesand...
(Date:11/24/2009)...elease is available in German . , Whether i...ds: RFID tags (Radio Frequency Identification) are.... They make it possible to label objects or goods .... The appropriate scanner can read and process the...affixed to goods under production conditions of up...
(Date:11/24/2009)... The New York investment bank KTA ...EU) has agreed an AU$6.7 mil convertible note priv...The private placement was arranged by KTA Capital ... , New York (PRWEB) Novem...t bank KTA Capital, LLC ("KTA Capital") ...
(Date:11/24/2009)...EYKJAVIK,Iceland,November24/PRNewswire-FirstCall/-...thatithasreceivednoticefrom,theNasdaqStockMarketth...asofNovember30,2009andaForm25-NSEwillbefiledwithth...eCODE,scommonstock,fromlistingonNasdaq,unlesstheco...sPanel.Thecompanyhasfiledsuchanappeal,which,willst...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...ceutical Communication Event, Where Executives Ga...R &, Communications Summit for Pharmaceutical, Bi... Companies, NEW YORK, May 29 ExL Pharma ...e the participation of two keynote speakers from t...uring the 4th Annual Public,Relations and Communic...
...idates the critical role of self-care in...May 29 InterCure Ltd., a medical device,company p...E: INCR), today,announced its support of the new j...Association, American Society of Hypertension and ...declaring that people with,hypertension should rou...
...nch of Nine Emerging Therapies, Including Five Or... Resources, WALTHAM...rld,s leading research and advisory firms for phar...ighly anticipated launch of the first,oral agents ...e market,growth as these therapies, combined, will...
Other Biology Technology:FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring 2InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring 3Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017 2
(Date:11/24/2009)...ed a protein that may help gut bacteria bind to th...d by probiotic producers to identify strains that ...obiotics need to interact with cells lining the gu...to surfaces in the gut they are more likely to sti...ys Dr Nathalie Juge from the Institute of Food Res...
(Date:11/24/2009)...November 24, 2009) -- The Wildlife Conservation So...t the last remaining population of Siberian tigers...ng tide of poaching and habitat loss. , ...fficials of what needs to be done to protect remai... The report was released by the Siberia...
(Date:11/24/2009)... in Spanish . , The presence of increased b...ry substances in the blood, hinders the loss and m...project of the University of Navarra conducted by ...l of Pharmacy. , The project, entitled "A nutrig...ontrol of body weight and inflammation," examines ...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2It can be predicted the reaction obese patients will have to a diet 2New strategy in tumor treatment 52140 1New strategy in tumor treatment 52140 2RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 52137 1RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 52137 2Breast cancer drug shows promise against serious infections 52134 1Breast cancer drug shows promise against serious infections 52134 2
... 2007 University of California, Irvine scientists...emory problems inherent in the most common form of...born and her colleagues identified how a mutated g...s from locking new memories into lasting ones. The...r1) -- is turned off in people with fragile X synd...
...vailabe in German . , In the ultimatum game -...h, now at the Max Planck Institute for Economics i...by an experimenter. That proposer can then divide ...responder. The responder is not powerless - if he ...fered amounts. But if he rejects it, both get noth...
...eads to under-consumption of calcium, according to...e the information consumed more. Researchers belie.... , A woman at risk for osteoporosis is told by he...every day. But when she looks at the Nutrition Fac...he finds that calcium is only listed by Percent Da...
Other Biology News:UCI researchers restore memory process in most common form of mental disability 2Fair play in chimpanzees 2Got calcium? UWM researcher finds that food labels confuse consumers 2Got calcium? UWM researcher finds that food labels confuse consumers 3
Mouse Anti-Plastin L Monoclonal Antibody, Unconjugated, Clone LPL4A.1 from Abcam
HyperMu Transposon from EPICENTRE Biotechnologies
Rhesus Macaque IFN-alpha from R&D Systems
Sheep Anti-chk 1 kinase Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
Biology Products: